TABLE 3.
Characteristics of the patients with graft failure
| Diagnosis | Age | Sex | CD34+ dose (cells × 106/kg) | CD19+ dose (cells × 105/kg) | TCR αβ+ dose (cells × 105/kg) | Conditioning regime | CMV serostatus (donor/recipient) | Viral reactivation | Outcome after HSCT |
|---|---|---|---|---|---|---|---|---|---|
| ALL | 3.5 | F | 7 | 0.06 | 1.9 | BU/FLU/TT | +/+ | No | Dead |
| ALL | 2.9 | M | 14 | 0.15 | 0.18 | BU/FLU/TT/rAGT | +/+ | Yes (HHV6) | Autologous recovery |
| ALL | 3.5 | F | 14 | 0.07 | 0.39 | BU/FLU/TT/rAGT | +/+ | No | Autologous recovery |
| ALL | 3.4 | F | 5.22 | 0.1 | 1 | BU/FLU/TT/rAGT | +/+ | No | Autologous recovery |
| AML | 9.0 | M | 10.60 | 5.52 | 1.61 | FLU/ rAGT/TBI/CY | +/+ | No | Dead |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; BU, busulfan: CY, cyclophosphamide: F, female; FLU, fludarabine: M, male; rATG, rabbit anti-thymocyte globulin: TBI, total body irradiation; TT, thiotepa.